Cowen and Company reaffirmed their outperform rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a research report released on Saturday, July 22nd. They currently have a $120.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $91.00.
Other equities research analysts have also recently issued research reports about the stock. Bank of America Corporation increased their target price on shares of Puma Biotechnology from $72.00 to $86.00 and gave the company a buy rating in a research report on Thursday, May 25th. Stifel Nicolaus reissued a buy rating and set a $88.00 target price on shares of Puma Biotechnology in a research report on Wednesday, April 19th. Zacks Investment Research raised shares of Puma Biotechnology from a hold rating to a buy rating and set a $59.00 price target for the company in a report on Wednesday, May 24th. Credit Suisse Group set a $58.00 price target on shares of Puma Biotechnology and gave the stock a buy rating in a report on Monday, May 22nd. Finally, Citigroup Inc. reaffirmed a buy rating and issued a $88.00 price target on shares of Puma Biotechnology in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Puma Biotechnology presently has a consensus rating of Buy and an average price target of $109.56.
Shares of Puma Biotechnology (NYSE:PBYI) traded down 1.18% during trading on Friday, reaching $79.75. 744,991 shares of the company were exchanged. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $98.85. The company’s 50-day moving average is $87.66 and its 200 day moving average is $58.07. The firm’s market capitalization is $2.97 billion.
In related news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of the firm’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $75.38, for a total transaction of $93,147,066.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alan H. Auerbach sold 13,175 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the sale, the insider now owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,010,261 shares of company stock valued at $159,425,452. 22.70% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in Puma Biotechnology by 2.4% in the first quarter. FMR LLC now owns 3,540,729 shares of the biopharmaceutical company’s stock valued at $131,715,000 after buying an additional 81,410 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Puma Biotechnology by 7.2% in the first quarter. Wellington Management Group LLP now owns 2,539,350 shares of the biopharmaceutical company’s stock valued at $94,464,000 after buying an additional 170,812 shares during the period. Vanguard Group Inc. raised its stake in shares of Puma Biotechnology by 1.9% in the second quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock valued at $216,284,000 after buying an additional 45,735 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Puma Biotechnology during the second quarter valued at about $162,302,000. Finally, BlackRock Inc. raised its stake in shares of Puma Biotechnology by 5.0% in the second quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock valued at $159,973,000 after buying an additional 86,924 shares during the period. Institutional investors own 80.98% of the company’s stock.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
What are top analysts saying about Puma Biotechnology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puma Biotechnology Inc and related companies.